Fibrinogen preparations enriched in fibrinogen with an extended alpha chain
View Patent ↗The present invention relates to fibrinogen preparations enriched in α-extended fibrinogen. Compositions comprising such preparations show improved clotting properties compared to preparations based on HMW Fib which typically contain no or only low amounts of α-extended fibrinogen. In particular, clot formation time and the clot strength of a clot made by α-extended fibrinogen are improved. In addition, plasmin-mediated degradation of α-extended fibrinogen is reduced as compared to plasma derived fibrinogen.
1. A method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders, comprising administering to a human in need thereof an effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises:
a human fibrinogen preparation, and
a pharmaceutically acceptable carrier, diluent or excipient,
wherein the human fibrinogen preparation comprises at least 95% (w/w) fibrinogen based on total protein,
wherein at least 10% (w/w) of the fibrinogen is in the form of fibrinogen with an extended alpha polypeptide chain (Fib420),
wherein the Fib420 is prepared by recombinant technology,
wherein the Fib420 is prepared by a method comprising the steps of:
a) providing an expression vector comprising a nucleotide sequence encoding the alpha extended polypeptide chain of Fib420;
b) transforming a mammalian cell with the expression vector, and
c) maintaining the transformed mammalian cell under such conditions which allow for the expression of the nucleotide sequence encoding the alpha extended polypeptide chain of Fib420, and
wherein the nucleotide sequence comprises SEQ ID NO. 5 or nucleotides 69-2598 of SEQ ID NO. 5.
2. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the nucleotide sequence encoding an alpha extended polypeptide chain of Fib420 is a codon optimized sequence that is optimized for expression in mammalian cell culture system, wherein the optimized sequence shows at least 70% identity to its respective wild type counterpart.
3. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the mammalian cell is a human cell.
4. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the mammalian cell is a PER.C6 cell as deposited under European Collection of Animal Cell Cultures (ECACC) No. 96022940.
5. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the human fibrinogen preparation is free of Factor XIII.
6. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the pharmaceutical composition is administered intravenously.
7. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the pharmaceutical composition is administered topically.
8. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the pharmaceutical composition is suitable for facilitating tissue adherence, or improving wound healing.
9. The method of treating acute bleeding episodes, hyperfibrinolysis, fibrinogen deficiency or other bleeding disorders of claim 1 , wherein the pharmaceutical composition is a fibrin sealant or a topical haemostat.